| Id |
Subject |
Object |
Predicate |
Lexical cue |
| SS1_24280231_2_0 |
1739-1964 |
expanded |
denotes |
h Network (UKCRN) Portfolio Database, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO and National Library of Medicine (NLM) Gateway, Cochrane Central Register of Controlled Trials (CENTRAL), Curre |
| SS2_24280231_2_0 |
2236-2358 |
abbr |
denotes |
HODS: Systematic reviews of evidence on clinical effectiveness and cost-effectiveness of second- and third-generation US F |
| SS1_24280231_2_1 |
3380-3719 |
expanded |
denotes |
h MM or as ATT compared with BTT. Approximately 15-25% of the patients receiving a device had died by 12 months. Studies reported the following wide ranges for adverse events: 4-27% bleeding requiring transfusion; 1.5-40% stroke; 3.3-48% infection; 1-14% device failure; 3-30% HF; 11-32% reoperation; and 3-53% renal failure. QoL and funct |
| SS2_24280231_2_1 |
3799-3806 |
abbr |
denotes |
HMII; T |
| SS1_24280231_4_0 |
485-511 |
expanded |
denotes |
Ventricular assist devices |
| SS2_24280231_4_0 |
513-517 |
abbr |
denotes |
VADs |
| SS1_24280231_4_1 |
561-586 |
expanded |
denotes |
alternative to transplant |
| SS2_24280231_4_1 |
588-591 |
abbr |
denotes |
ATT |
| SS1_24280231_4_2 |
601-621 |
expanded |
denotes |
bridge to transplant |
| SS2_24280231_4_2 |
623-626 |
abbr |
denotes |
BTT |
| SS1_24280231_8_0 |
1062-1080 |
expanded |
denotes |
medical management |
| SS2_24280231_8_0 |
1082-1084 |
abbr |
denotes |
MM |
| SS1_24280231_10_0 |
1444-1483 |
expanded |
denotes |
Cochrane Database of Systematic Reviews |
| SS2_24280231_10_0 |
1485-1489 |
abbr |
denotes |
CDSR |
| SS1_24280231_10_1 |
1492-1535 |
expanded |
denotes |
Database of Abstracts of Reviews of Effects |
| SS2_24280231_10_1 |
1537-1541 |
abbr |
denotes |
DARE |
| SS1_24280231_10_2 |
1544-1576 |
expanded |
denotes |
NHS Economic Evaluation Database |
| SS2_24280231_10_2 |
1578-1585 |
abbr |
denotes |
NHS EED |
| SS1_24280231_10_3 |
1607-1643 |
expanded |
denotes |
Centre for Reviews and Dissemination |
| SS2_24280231_10_3 |
1645-1648 |
abbr |
denotes |
CRD |
| SS1_24280231_10_4 |
1720-1748 |
expanded |
denotes |
UK Clinical Research Network |
| SS2_24280231_10_4 |
1750-1755 |
abbr |
denotes |
UKCRN |
| SS1_24280231_10_5 |
1777-1833 |
expanded |
denotes |
Cumulative Index to Nursing and Allied Health Literature |
| SS2_24280231_10_5 |
1835-1841 |
abbr |
denotes |
CINAHL |
| SS1_24280231_10_6 |
1857-1885 |
expanded |
denotes |
National Library of Medicine |
| SS2_24280231_10_6 |
1887-1890 |
abbr |
denotes |
NLM |
| SS1_24280231_10_7 |
1910-1947 |
expanded |
denotes |
Central Register of Controlled Trials |
| SS2_24280231_10_7 |
1949-1956 |
abbr |
denotes |
CENTRAL |
| SS1_24280231_12_0 |
2143-2166 |
expanded |
denotes |
individual patient data |
| SS2_24280231_12_0 |
2168-2171 |
abbr |
denotes |
IPD |
| SS1_24280231_12_1 |
2188-2217 |
expanded |
denotes |
Blood and Transplant Database |
| SS2_24280231_12_1 |
2219-2223 |
abbr |
denotes |
BTDB |
| SS1_24280231_14_0 |
2357-2385 |
expanded |
denotes |
Food and Drug Administration |
| SS2_24280231_14_0 |
2387-2390 |
abbr |
denotes |
FDA |
| SS1_24280231_14_1 |
2399-2549 |
expanded |
denotes |
Conformité Européenne (CE) approved VADs. Publications from the last 5 years with control groups, or case series with 50 or more patients were include |
| SS2_24280231_14_1 |
3007-3009 |
abbr |
denotes |
CE |
| SS1_24280231_16_0 |
2671-2686 |
expanded |
denotes |
quality of life |
| SS2_24280231_16_0 |
2688-2691 |
abbr |
denotes |
QoL |
| SS1_24280231_20_0 |
2967-3004 |
expanded |
denotes |
incremental cost-effectiveness ratios |
| SS2_24280231_20_0 |
3006-3011 |
abbr |
denotes |
ICERs |
| SS1_24280231_20_1 |
3019-3046 |
expanded |
denotes |
quality-adjusted life-years |
| SS2_24280231_20_1 |
3048-3053 |
abbr |
denotes |
QALYs |
| SS1_24280231_20_2 |
3071-3087 |
expanded |
denotes |
life-year gained |
| SS2_24280231_20_2 |
3089-3092 |
abbr |
denotes |
LYG |
| SS1_24280231_27_0 |
3785-3797 |
expanded |
denotes |
HeartMate II |
| SS2_24280231_27_0 |
3799-3803 |
abbr |
denotes |
HMII |
| SS1_24280231_27_1 |
3845-3854 |
expanded |
denotes |
HeartWare |
| SS2_24280231_27_1 |
3856-3858 |
abbr |
denotes |
HW |
| SS1_24280231_33_0 |
4520-4548 |
expanded |
denotes |
randomised controlled trials |
| SS2_24280231_33_0 |
4550-4554 |
abbr |
denotes |
RCTs |
| AE1_24280231_2_0 |
SS1_24280231_2_0 |
SS2_24280231_2_0 |
abbreviatedTo |
"h Network (UKCRN) Portfolio Database, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycINFO and National Library of Medicine (NLM) Gateway, Cochrane Central Register of Controlled Trials (CENTRAL), Curre",HODS: Systematic reviews of evidence on clinical effectiveness and cost-effectiveness of second- and third-generation US F |
| AE1_24280231_2_1 |
SS1_24280231_2_1 |
SS2_24280231_2_1 |
abbreviatedTo |
h MM or as ATT compared with BTT. Approximately 15-25% of the patients receiving a device had died by 12 months. Studies reported the following wide ranges for adverse events: 4-27% bleeding requiring transfusion; 1.5-40% stroke; 3.3-48% infection; 1-14% device failure; 3-30% HF; 11-32% reoperation; and 3-53% renal failure. QoL and funct,HMII; T |
| AE1_24280231_4_0 |
SS1_24280231_4_0 |
SS2_24280231_4_0 |
abbreviatedTo |
Ventricular assist devices,VADs |
| AE1_24280231_4_1 |
SS1_24280231_4_1 |
SS2_24280231_4_1 |
abbreviatedTo |
alternative to transplant,ATT |
| AE1_24280231_4_2 |
SS1_24280231_4_2 |
SS2_24280231_4_2 |
abbreviatedTo |
bridge to transplant,BTT |
| AE1_24280231_8_0 |
SS1_24280231_8_0 |
SS2_24280231_8_0 |
abbreviatedTo |
medical management,MM |
| AE1_24280231_10_0 |
SS1_24280231_10_0 |
SS2_24280231_10_0 |
abbreviatedTo |
Cochrane Database of Systematic Reviews,CDSR |
| AE1_24280231_10_1 |
SS1_24280231_10_1 |
SS2_24280231_10_1 |
abbreviatedTo |
Database of Abstracts of Reviews of Effects,DARE |
| AE1_24280231_10_2 |
SS1_24280231_10_2 |
SS2_24280231_10_2 |
abbreviatedTo |
NHS Economic Evaluation Database,NHS EED |
| AE1_24280231_10_3 |
SS1_24280231_10_3 |
SS2_24280231_10_3 |
abbreviatedTo |
Centre for Reviews and Dissemination,CRD |
| AE1_24280231_10_4 |
SS1_24280231_10_4 |
SS2_24280231_10_4 |
abbreviatedTo |
UK Clinical Research Network,UKCRN |
| AE1_24280231_10_5 |
SS1_24280231_10_5 |
SS2_24280231_10_5 |
abbreviatedTo |
Cumulative Index to Nursing and Allied Health Literature,CINAHL |
| AE1_24280231_10_6 |
SS1_24280231_10_6 |
SS2_24280231_10_6 |
abbreviatedTo |
National Library of Medicine,NLM |
| AE1_24280231_10_7 |
SS1_24280231_10_7 |
SS2_24280231_10_7 |
abbreviatedTo |
Central Register of Controlled Trials,CENTRAL |
| AE1_24280231_12_0 |
SS1_24280231_12_0 |
SS2_24280231_12_0 |
abbreviatedTo |
individual patient data,IPD |
| AE1_24280231_12_1 |
SS1_24280231_12_1 |
SS2_24280231_12_1 |
abbreviatedTo |
Blood and Transplant Database,BTDB |
| AE1_24280231_14_0 |
SS1_24280231_14_0 |
SS2_24280231_14_0 |
abbreviatedTo |
Food and Drug Administration,FDA |
| AE1_24280231_14_1 |
SS1_24280231_14_1 |
SS2_24280231_14_1 |
abbreviatedTo |
"Conformité Européenne (CE) approved VADs. Publications from the last 5 years with control groups, or case series with 50 or more patients were include",CE |
| AE1_24280231_16_0 |
SS1_24280231_16_0 |
SS2_24280231_16_0 |
abbreviatedTo |
quality of life,QoL |
| AE1_24280231_20_0 |
SS1_24280231_20_0 |
SS2_24280231_20_0 |
abbreviatedTo |
incremental cost-effectiveness ratios,ICERs |
| AE1_24280231_20_1 |
SS1_24280231_20_1 |
SS2_24280231_20_1 |
abbreviatedTo |
quality-adjusted life-years,QALYs |
| AE1_24280231_20_2 |
SS1_24280231_20_2 |
SS2_24280231_20_2 |
abbreviatedTo |
life-year gained,LYG |
| AE1_24280231_27_0 |
SS1_24280231_27_0 |
SS2_24280231_27_0 |
abbreviatedTo |
HeartMate II,HMII |
| AE1_24280231_27_1 |
SS1_24280231_27_1 |
SS2_24280231_27_1 |
abbreviatedTo |
HeartWare,HW |
| AE1_24280231_33_0 |
SS1_24280231_33_0 |
SS2_24280231_33_0 |
abbreviatedTo |
randomised controlled trials,RCTs |
